Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary
Grace Therapeutics (GRCE) reported a Q1 2027 net loss of $15.8M for the quarter ended June 30, 2026, versus a $3.4M loss a year earlier. Diluted EPS was $(0.91) versus $(0.21). Revenue was not reported. The company received an FDA Complete Response Letter for GTx-104, citing CMC and nonclinical items, and is pursuing an NDA resubmission.
How this was made
The 30-second read
Why it matters
The FDA CRL is the dominant new risk factor, while the Phase 3 STRIVE-ON primary endpoint success provides a counterweight for the clinical narrative. The funding discontinuation for GTx-101 and GTx-102 suggests management is concentrating resources on GTx-104’s regulatory path.
Market read
Traders can reassess GTx-104’s regulatory timeline and probability-weighted path to NDA resubmission after the CRL, while monitoring whether manufacturing and CMC actions address the FDA’s remaining concerns.
What to watch
The company also initiated dual-source manufacturing and a US tech transfer to reduce cGMP single-source risk, which could shorten the path to an acceptable NDA resubmission if executed on schedule.
Background
The piece summarizes Grace Therapeutics’ Q1 2027 (quarter ended June 30, 2026) 10-Q and key business updates, including an FDA Complete Response Letter for lead asset GTx-104.
Ticker impact
Grace Therapeutics received an FDA Complete Response Letter for GTx-104 and is pursuing an NDA resubmission after CMC and nonclinical items.
Near-term downside bias on regulatory overhang, with volatility driven by NDA resubmission progress and any follow-on FDA feedback.
The article discloses a new FDA Complete Response Letter and details what remains outstanding (CMC and nonclinical), which typically pressures valuation until resubmission acceptance.
Market effects
Highlights ongoing FDA scrutiny around CMC and nonclinical items for late-stage programs, reinforcing higher diligence on resubmission readiness.
No specific regional market linkage beyond US FDA regulatory process.
Limited, as the catalyst is US FDA-specific for a single lead asset.
Counterpoint
The CRL cites no clinical deficits, so the core efficacy story may remain intact, making the resubmission a technical fix rather than a clinical failure.
Key entities
- companyGrace Therapeutics, Inc.
Subject of the 10-Q summary, including FDA CRL for GTx-104 and Phase 3 STRIVE-ON endpoint results.
- drug_programGTx-104
Lead asset that received an FDA Complete Response Letter; outstanding items relate to CMC and nonclinical matters.
- drug_programGTx-101 and GTx-102
Internal development funding was discontinued, with full IPR&D impairments recorded.
- clinical_trialSTRIVE-ON
Phase 3 program that met its primary endpoint, showing reduced hypotension and improved outcomes.
